CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Rabbit Antithymocyte Globulin +2 moredrug
Likely dose
Rabbit Antithymocyte Globulin 1.5mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00782821
NCT00782821Phase 4Completed

Targeted Therapy for High Immunologic Risk Renal Transplant Recipients: A Prospective, Randomized, Open-Label Pilot Study of B-Cell Depleting Therapy in Combination With Anti-Thymocyte Globulin [Rabbit] (Thymoglobulin®, Genzyme), Tacrolimus (Prograf®, Astellas), Mycophenolate Mofetil (CellCept®, Roche) and Corticosteroid Minimization

University of Cincinnati·interventional·Posted Oct 31, 2008·Updated Jan 20, 2016

In Brief

A Phase 4 clinical trial evaluating Rabbit Antithymocyte Globulin, Velcade, and 1 other intervention for Kidney Transplantation. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

The purpose of this research study is to find out the effects of adding B lymphocyte modulating agents in patients at risk for rejection receiving an anti-rejection (immunosuppressive) regimen of Thymoglobulin® induction with Prograf®, Cellcept® and corticosteroid therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 31, 2008
Enrollment StartSep 1, 2008
Primary CompletionFeb 1, 2013
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 17.7 years ago

Interventions

Rabbit Antithymocyte Globulindrug

rATG will be given 1.5mg/kg intravenous (IV) per dose.

Velcadedrug

Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.

Rituxandrug

Given via IV per group assignment.